

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <b>014835.77.02-034</b>		SERIAL NO. <b>10/527,904</b>	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b>				APPLICANT <b>Redfield, et al.</b>			
				FILING DATE <b>07-07-2005</b>		GROUP 1617	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINE R INITIAL		PATENT or APPLICATION NUMBER	ISSUE OR PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,114,957	5/19/1992	Hendler, et al			
		DOCUMENT NUMBER	PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	CLASS	SUBCLASS	TRANSLATION YES   NO
		2006/0154857	7/13/2006	Redfield, et al.			
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
		Golub, et al, (1991) Induction of Dornat HIV-1 by Sodium Butyrate: Aids, Vol 5, No. 6, pages 663-668					
		Korin, et al., (1998) Progression to the G1b phase of the cell cycles is required for completion of human Immunodeficiency virus type 1 reverse transcription in T cells, Journal of Virology, Vol. 72, No. 4, pages 3161-3168					
		Vila, et al. (1996) 1year follow-up of the use of hydroxycarbamide and didanosine in HIV infection, Lancet, Vol 348, No. 9021, pages 203-204					
		Quivy, et al., (2002) Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases. Journal of Virology, Vol. 76, No.21, page 11102					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							